Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research, has officially joined Eli Lilly to lead research and development in infectious diseases and molecule discovery. This career move comes just months after Marks’ high-profile departure from the agency, where he was a pivotal figure in the United States COVID-19 vaccine approval process.
Marks’ recruitment by Lilly was confirmed this week, with the company highlighting his “tremendous experience and background” as vital assets in accelerating breakthroughs across its portfolio. His new executive role at Lilly Research Laboratories started Monday, marking one of the year’s most watched transitions between federal regulatory leadership and industry.
During his nearly decade-long tenure at the FDA, Marks oversaw reviews of vaccines, cell and gene therapies, and played a leading role in the agency’s pandemic response and rapid development of new biologic medicines. At Lilly, Marks will help steer strategic efforts in infectious disease research, a sector that has grown in importance as global drugmakers race to expand vaccine and antiviral innovation.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!